156 results
Page 5 of 8
8-K
EX-99.1
chfwymmptm
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-10.3
24pd3n0b6 0s6ch7hr
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.1
tf3 nt4ceb
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.1
7zi20xm
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-10.3
rn6iw7k 2sytkxdql
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
tdz0t2j
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
p5k9t01truj56y605ts
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.1
be8uph omoa1n69
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.4
qpx15t fk9i3oi
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
xs4z6sex7 d6dn
20 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-1.1
3bgl fpqb
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
jm3y7yrc
27 Nov 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
x06z8c6nnbkfy9np
20 Nov 19
Other Events
7:05am
8-K
EX-99.1
gqs3xufkq jh3t4o459e
8 Nov 19
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
2:33pm
8-K
EX-99.1
vqmfae9koy
7 Nov 19
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.2
6w0u620ibkh7
27 Sep 19
Other Events
10:15am